News Headlines Article

FDA panel backs Pfizer drug for kidney cancer
USA Today

A panel of advisers to the Food and Drug Administration has voted that the benefits of a Pfizer kidney cancer drug outweigh its risks. The FDA’s panel of 13 cancer experts unanimously backed the benefits of Pfizer’s axitinib for kidney cancer patients who have not responded well to at least one other drug. The agency is not required to approve drugs backed by the panel, though it often does.